Индуцированная циклофосфаном иммуносупрессия и ее коррекция иммуномодулятором микробного происхождения
Диссертация
Апробация работы. Материалы диссертационной работы представлены и обсуждены: на X Всероссийском научном Форуме, 29 мая-1 июня, 2006, г. Санкт-Петербургна VIII Конгрессе «Современные проблемы аллергологии, иммунологии и иммунофармакологии», 27−29 июня 2007, г. Москвана XI Всероссийском научном Форуме, 28−31 мая 2007, г. Санкт-Петербургна Международной научной конференции «Фундаментальные… Читать ещё >
Содержание
- 1. Обзор литературы
- Иммунодефицитные состояния в онкологии
- Иммуносупрессия на фоне проводимого лечения
- Коррекция ХТ-индуцированной иммуносупрессии
- Экспериментальные модели оценки иммуномодулирующих средств
- Одновременный метаболизм веществ в организме
- 2. Материалы и методы
- 2. 1. Объекты исследования
- 2. 2. Использованные препараты и способы их введения
- 2. 3. Биохимические методы исследования
- 2. 3. 1. Определение фармакокинетики циклофосфана
- 2. 3. 1. 1. Определения активных метаболитов циклофосфана в плазме крови мышей
- 2. 3. 1. 2. Определение периода полуэлиминации метаболитов циклофосфана графическим методом
- 2. 3. 1. Определение фармакокинетики циклофосфана
- 2. 4. Определение количества лейкоцитов периферической крови мышей
- 2. 4. 1. Определение общетоксического действия циклофосфана
- 2. 5. Определение противоопухолевого действия ЦФ
- 2. 5. 2. Цитотоксический тест
- 2. 5. 3. Культивирование клеток К
- 2. 6. Иммунологические методы
- 2. 6. 1. Определение иммуносупрессорного действия ЦФ
- 2. 6. 2. Оценка субпопуляционного состава лимфоцитов
- 2. 6. 3. Определение цитокинового профиля в сыворотке крови мышей линии СВА
- 2. 6. 4. Определение спонтанной и индуцированной продукции цитокинов спленоцитами мышей
- 2. 7. Цитологические, морфогистохимические методы исследования
- 2. 7. 1. Цитологическое исследование
- 2. 7. 2. Определение морфологических и гистохимических изменений в мазках культуральной клеточной взвеси и периферической крови мышей
- 2. 7. 3. Определение морфологических и гистохимических изменений в паренхиматозных и иммунокомпетентных органах мышей
- 2. 7. 4. Анализ изображений и фотографирование
- 2. 8. Статистические методы
- 3. 1. Фармакодинамика многократных введений циклофосфана
- 3. 1. Изучение фармакодинамики и токсичности ЦФ при разных режимах введения
- 3. 1. 1. Изучение общетоксического действия ЦФ
- 3. 2. Изучение влияния ВП-4 на терапевтический и токсический эффект ЦФ
- 3. 2. 1. Изучение влияния ВП-4 на фармакокинетику реактивных метаболитов циклофосфана в зависимости от режима введения ЦФ
- 3. 2. 2. Изучение влияния ВП-4 на терапевтическую эффективность многократного введения ЦФ
- 3. 3. Изучение морфогистохимических изменений органов гемоиммунопоэза и периферической крови мышей на фоне индуцированной иммуносупрессии и возможностей коррекции
- 3. 3. 1. Оценка изменений количества и субпопуляционного состава мононуклеарных лейкоцитов в селезенке экспериметальных мышей
- 3. 3. 2. Морфогистохимические изменения органов гемоиммунопоэза у экспериментальных мышей
- 3. 4. Изменения цитокинового профиля мышей с индуцированной иммуносупрессией и их коррекция при действии ВП
Список литературы
- Александров Н.Н., Савченко Н. Е., Фрадкин С.З., et al., Применение гипертермии и гипергликемии при лечении злокачественных опухолей//М.:Meдицина. 1980. 256.
- Ахматова Н.К., Киселевский М. В., Курбатова Е.А., et al., Влияние поликомпонентной вакцины ВП-4 на цитотоксическую активность мононуклеаров периферической крови здоровых доноров. Бюллетень экспериментальной биологии, 2005.
- Богуш Т.А., Монооксигеназы печени и действие противоопухолевых препаратов/эксперименталыю-клиническое исследование/. Диссертация на соискание ученой степени доктора биологических наук. Москва. 1985.
- Ванько Л.В., Сухих Т. Г., Естественная цитотоксическая активность клеток костного мозга и селезенки мыши в прогрессе регенерации после воздействия циклофосфамида. Бюлл. эксп. биол. и мед., 1983. XXVI (12): р. 84−86.
- Дыгай A.M., Жданов М. М., Минакова М.Ю., et al., Роль процессов пролиферации и дифференцировки кроветворных клеток-предшественников в восстановлении гемопоэза при цитостатических миелосупрессиях. Бюлл. Экспер. Биол. и Мед., 1997. 124(12): р. 616−620.
- Дыгай A.M., Жданов М. М., Минакова М.Ю., et al., Участие гуморальных факторов в регуляции кроветворения при цитостатических миелосупрессиях. Бюлл. Экспер. Биол. и Мед., 1997. 124(8): р. 161−165.
- Дыгай A.M., Жданов М. М., Хлусов И.А., et al., О регулирующем влиянии гемопоэзиндуцирующего микроокружения на процессы кроветворения при действии г^итостатиков. Гематол. и трансфузиол., 1995. 40(5): р. 11−15.
- Жданов М.М., Дыгай A.M., Минакова М.Ю., et al., Участие процессов связывания кроветворных клеток со стромалъными элементами костного мозга и восстановлении гемопоэза цитостатических миелосупрессиях. Гемотол. и трансфузиол, 1998. 43(4): р. 14−17.
- Запускалова О.Б., Морфофункционалъное состояниелимфоидной ткани через 1 месяц после введения циклофосфана в эксперименте. Механизмы патологических реакций, 1988. 5: р. 35−38.
- Запускалова О.Б., Богдашин И. В., Новицкий В. В., Коррекция диуцифоном нарушений иммунитета, вызванных введением цитостатических препаратов. Иммунология, 1990. 6: р. 24−27.
- Кабиева А.О., Доненко Ф. В., Модификация действия противоопухолевых лекарств локальной гипертермией и искусственной гипергликемией. Бюл. эксперим. биологии и медицины, 1990. 110(9): р. 310−312.
- Красноженов Е.П., Федоров Ю В., Чубик М. П., Влияние экспериментальной стафилококковой инфекции на морфофункционалъную характеристику тканевых базофилов и тучных клеток. Журн. микробиологии, эпидемиологии и иммунобиологии, 2000(1): р. 66−8.
- Лебединская О.В., Велижева Н. П., Доненко Ф. В., Влияние препарата профеталь на дифференцировку и функциональную активность мононуклеарных лейкоцитов человека. Клеточные технологии в биологии и медицине, 2006. 2: р. 108−11.
- Мусаев А.В., Багирова С. А., Магеррамова С.Е., et al., Влияние нафталана на фагоцитарные процессы перитонеальных макрофагов вусловиях вторичного иммунодефицита. Вопросы курортологии, физиотерапии и лечебной физической культуры, 2005(6): р. 10−2.
- Петров Р.В., Манько В. М., Иммунодепрессоры. М, 1971: р. 219−231.
- Потапова А.А., Максимова Г. Ф., Корсова Т. Л., Протективные эффекты бета-каротина при иммунодепрессии индуцированной гидрокортизоном in vivo. Иммунология, 1995. 5: р. 33−35.
- Сергеев П.В., Ухина Т. В., Семейкин А.В., et al., Стероидные гормоны -модуляторы липидногоспектра лизосомалъных мембран фибробластов кожи. Бюлл.экспер. биол. и мед., 1998. 125(2): р. 197−210.
- Софьина З.П., Экспериментальная оценка противоопухолевых препаратов в СССР и США -М.: Медицина. -1980.-296с.
- Стенина М.А., Воеводин Д. А., Скрипник A., et al., Роль дисбактериоза в формировании хронической неинфекционной патологии у детей. Журн. микробиологии, эпидемиологии и иммунобиологии, 2001(5): р. 50−4.
- Стеценко О.Н., Борзова Н. В., Линднер Д.П., et al., Влияние иммуномодулятора полиоксидония на восстановление костного мозга, поврежденного действием гидрокортизона и циклофосфана. Иммунология, 2005. 26(6): р. 365 -368.
- Фрадкин С.З., Жаврид Э. А., Небышевская Н.С., et al., Искусственная гипергликемия как фактор модификации чувствительности саркомы 45 к химиотерапии. Эксперим. Онкология, 1987. 9(3): р. 68−77.
- Шапот B.C., Биохимические аспекты опухолевого роста//М.:Медицина. 1975. 464.
- Ancona Е., Amadori G., Ninfo V., et al., Immune reactivity in patients with cancer of the esophagus. Minerva Med, 1979. 70(33): p. 2311−20.
- Biological response modifiers in human oncology and immunology. Adv Exp Med Biol, 1983. 166: p. 1−320.
- Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol, 1996. 14(6): p. 1957−60.
- Abayomi A., The human immunodeficiency virus epidemic: a race against time for millions and the role of flow cytometry. A Caribbean and resource-constrained country perspective. Cytometry B Clin Cytom, 2007. 72(6): p. 478−81.
- Alanko S., Salmi T.T., Pelliniemi T.T., Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumors. Med Pediatr Oncol, 1995. 24(6): p. 373−8.
- Alberts D.S., van Daalen Wetters T., The effect of phenobarbital on cyclophosphamide antitumor activity. Cancer Res, 1976. 36(8): p. 2785−9.
- Alpay H.C., Etem E.O., Kaygusuz I., et al., Evaluation of the polymorphism in the Toll-like receptor 4 (TLR4) genes of tympanosclerosis patients. Auris Nasus Larynx. 37(1): p. 29−32.
- Anderson R.B., Cianciolo G.J., Kennedy M.N., et al., Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism. J Leukoc Biol, 2008. 83(2): p. 381−92.
- Applegate K.G., Balch C.M., Pellis N.R., In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes. Cancer Res, 1990. 50(22): p. 7153−8.
- Artym J., Reconstitution of cyclophosphamide-induced, impaired function of the immune system in animal models., Postepy Hig Med Dosw, 2003. 57(1): p. 55−66.
- Artym J., Zimecki M., Kruzel M., Normalization of peripheral blood cell composition by lactoferrin in cyclophosphamide-treated mice. Med Sci Monit, 2004. 10(3): p. BR84−9.
- Audibert F., Jolivet M., Chedid L., et al., Successful immunization with a totally synthetic diphtheria vaccine. Proc Natl Acad Sci U S A, 1982. 79(16): p. 5042−6.
- Aune T.M., Role and function of antigen nonspecific suppressor factors. Crit Rev Immunol, 1987. 7(2): p. 93−130.
- Azuma E., Nagai M., Qi J., et al., CD4+ T-lymphocytopenia in long-term survivors following intensive chemotherapy in childhood cancers. Med Pediatr Oncol, 1998. 30(1): p. 40−5.
- Balow J.E., Hurley D.L., Fauci A.S., Cyclophosphamide suppression of established cell-mediated immunity. Quantitative vs. qualitative changes in lymphocyte populations. J Clin Invest, 1975. 56(1): p. 65−70.
- Barber G.N., Host defense, viruses and apoptosis. Cell Death Differ, 2001. 8(2): p. 113−26.
- Basu S., Bruce R.D., Barry D.T., et al., Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence. J Subst Abuse Treat, 2007. 32(4): p. 399−409.
- Bates S.E., Clinical applications of serum tumor markers. Ann Intern Med, 1991. 115(8): p. 623−38.
- Baxevanis C.N., Papamichail M., Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy. Crit Rev Oncol Hematol, 1994. 16(3): p. 157−79.
- Belardelli F., Ferrantini M., Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol, 2002. 23(4): p. 201−8.
- Ben-Efraim S., Keisari Y., Ophir R., et al., Immunopotentiating and immunotherapeutic effects of thymic hormones and factors with special emphasis on thymic humoral factor THF-gamma2. Crit Rev Immunol, 1999. 19(4): p. 261−84.
- Berd D., Maguire H.C., Jr., Mastrangelo M.J., Potentiation of human cellmediated and humoral immunity by low-dose cyclophosphamide. Cancer Res, 1984. 44(11): p. 5439−43.
- Bienz B., Zakut-Houri R., Givol D., et al., Analysis of the gene coding for the murine cellular tumour antigenp53. EMBO J, 1984. 3(9): p. 2179−83.
- Bodey G.P., Buckley M., Sathe Y.S., et al., Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med, 1966. 64(2): p. 328−40.
- Boon T., van der Bruggen P., Human tumor antigens recognized by T lymphocytes. J Exp Med, 1996. 183(3): p. 725−9.
- Brentlinger P.E., Behrens C.B., Kublin J.G., Challenges in the prevention, diagnosis, and treatment of malaria in human immunodeficiency virus infected adults in sub-Saharan Africa. Arch Intern Med, 2007. 167(17): p. 1827−36.
- Brittenden J., Heys S.D., Ross J., et al., Natural killer cells and cancer. Cancer, 1996. 77(7): p. 1226−43.
- Brode S., Cooke A., Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol, 2008. 28(2): p. 109−26.
- Brode S., Raine T., Zaccone P., et al., Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3 + regulatory T cells. J Immunol, 2006. 177(10): p. 6603−12.
- Brookes G.B., Clifford P., Nutritional status and general immune competence in patients with head and neck cancer. J R Soc Med, 1981. 74(2): p. 132−9.
- Brosens L.A., Tytgat K.M., Morsink F.H., et al., Midtiple colorectal neoplasms in X-linked agammaglobulinemia. Clin Gastroenterol Hepatol, 2008. 6(1): p. 115−9.
- Brostrom C.O., Pharmacological basis of therapeutics: vascular alpha-adrenoceptors. J Med Soc N J, 1985. 82(1): p. 59−61.
- Browell D.A., Lennard T.W., Immunologic status of the cancer patient and the effects of blood transfusion on antitumor responses. Curr Opin Gen Surg, 1993: p. 325−33.
- Bruserud 0., Ulvestad E., Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia. J Interferon Cytokine Res, 2000. 20(11): p. 947−54.
- Buonaguro L., Tornesello M.L., Buonaguro F.M., Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol, 2007. 81(19): p. 10 209−19.
- Cabrera T., Ruiz-Cabello F., Garrido F., Biological implications of HLA-DR expression in tumours. Scand J Immunol, 1995. 41(4): p. 398−406.
- Cameron D.J., Inhibitory factors derived from human tumors: isolation of factors which suppress macrophage mediated cytotoxicity. Int J Immunopharmacol, 1983. 5(4): p. 345−52.
- Caux C., Ait-Yahia S., Chemin K., et al., Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol, 2000. 22(4): p. 345−69.
- Chambers C.A., Kuhns M.S., Egen J.G., et al., CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol, 2001. 19: p. 565−94.
- Cheadle E.J., Jackson A.M., Bugs as drugs for cancer. Immunology, 2002. 107(1): p. 10−9.
- Chen X.M., Jiang H.L., Zhou L.F., et al., Immunomodulatory function of orally administered thymosin alphal. J Zhejiang Univ Sci B, 2005. 6(9): p. 873−6.
- Chen X.T., Li J., Wang H.L., et al., Immunomodidating effects of fractioned polysaccharides isolated from Yu-Ping-Feng-Powder in cyclophosphamide-treatedmice. Am J Chin Med, 2006. 34(4): p. 631−41.
- Chen Z., Dehm S., Bonham K., et al., DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol, 2001. 214(1): p. 60−71.
- Cheng Y.S., Xu F., Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 10(12): p. 1219−23.
- Cho W.C., Leung K.N., In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol, 2007. 113(1): p. 132−41.
- Chorba T.L., Nkengasong J., Roels T.H., et al., Assessing eosinophil count as a marker of immune activation among human immunodeficiency virus-infected persons in sub-Saharan Africa. Clin Infect Dis, 2002. 34(9): p. 1264−6.
- Chuang Y.H., Lian Z.X., Yang G.X., et al., Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominantnegative mouse model of primary biliary cirrhosis. Hepatology, 2008. 47(2): p. 571−80.
- Clough E.R., Audibert F.M., Barnwell J.W., et al., Biologically active antibodies elicited by a synthetic circumsporozoite peptide of Plasmodium knowlesi administered in saline with a muramyl dipeptide derivative. Infect Immun, 1985. 48(3): p. 839−42.
- Cole W.H., Humphrey L., Need for immunologic stimulators during immunosuppression produced by major cancer surgery. Ann Surg, 1985. 202(1): p. 9−20.
- Dewys W.D., Begg C., Lavin P.T., et al., Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med, 1980. 69(4): p. 491−7.
- Dhodapkar M.V., Bhardwaj N., Active immunization of humans with dendritic cells. J Clin Immunol, 2000. 20(3): p. 167−74.
- Dietrich F.M., Dukor P., The immune response to heterologous red cells in mice. 3. Cyclophosphamide-induced tolerance to multispecies rd cells. Pathol Microbiol (Basel), 1967. 30(6): p. 909−17.
- Dietrich F.M., Dukor P., The immune response to heterologous red cells in mice. IV. Induction of unresponsiveness to weakly immunogenic red cells by cyclophosphamide and cortisone acetate. Clin Exp Immunol, 1968. 3(8): p. 783−93.
- Divino C.M., Chen S.H., Yang W., et al., Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Res Treat, 2000. 60(2): p. 129−34.
- Donawho C.K., Kripke M.L., Immunologic factors in melanoma. Clin Dermatol, 1992. 10(1): p. 69−74.
- Dracott B.N., Smith C.E., Hydrocortisone and the antibody response in mice.
- Correlations between serum Cortisol levels and cell numbers in thymus, spleen, marrow and lymph nodes. Immunology, 1979. 38(2): p. 429−35.
- Dracott B.N., Smith C.E., Hydrocortisone and the antibody response in mice.1. Correlations between serum and antibody and PFC in thymus, spleen, marrow and lymph nodes. Immunology, 1979. 38(2): p. 437−43.
- Ehrke M.J., Effect of cancer therapy on host response and immunobiology. Curr Opin Oncol, 1991. 3(6): p. 1070−7.
- Ehrke M.J., Mihich E., Berd D., et al., Effects of anticancer drugs on the immune system in humans. Semin Oncol, 1989. 16(3): p. 230−53.
- Emsley H.C., Smith C.J., Hopkins S.J., Infection and brain-induced immunodepression after acute ischemic stroke. Stroke, 2008. 39(1): p. e7- author reply e8.
- Ershler W.B., The influence of an aging immune system on cancer incidence and progression. J Gerontol, 1993. 48(1): p. B3−7.
- Fabian J., Katz I., Gerntholtz T., et al., Chronic kidney disease in human immunodeficiency virus infection. Panminerva Med, 2007. 49(2): p. 51−66.
- Feldman R.L., Nickell K., Avian influenza: potential impact on sub-Saharan military populations with high rates of human immunodeficiency virus/acquired immunodeficiency syndrome. Mil Med, 2007. 172(7): p. 7538.
- Fernandez N.C., Flament C., Crepineau F., et al., Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw, 2002. 13(1): p. 17−27.
- Flajnik M.F., Advances in immunology. Bioessays, 1994. 16(9): p. 671−5.
- Forni G., Boggio K., Cytokine gene-engineered vaccines. Curr Opin Mol Ther, 1999.1(1): p. 34−8.
- Foss F.M., Immunologic mechanisms of antitumor activity. Semin Oncol, 2002. 29(3 Suppl 7): p. 5−11.
- Francis D.M., Shenton B.K., Proud G., et al., Immunosuppressive plasma factors in malignant disease. Aust N Z J Surg, 1985. 55(2): p. 111−20.
- Friedman O.M., Boger E., Grubliauskas V., et al., Synthesis of N-Phosphorylated Derivatives of Nitrogen Mustards with Latent Cytotoxicity. J Med Chem, 1963. 6: p. 50−8.
- Fry T.J., Christensen B.L., Komschlies K.L., et al., Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood, 2001. 97(6): p. 1525−33.
- Fry T.J., Connick E., Falloon J., et al., A potential role for interleukin-7 in T-cell homeostasis. Blood, 2001. 97(10): p. 2983−90.
- Gnanamony M., Peedicayil A., Abraham P., An overview of human papillomaviruses and current vaccine strategies. Indian J Med Microbiol, 2007. 25(1): p. 10−7.
- Good R.A., Fernandes G., Nutrition, immunity, and cancer-a review. Part I: Influence of protein or protein-calorie malnutrition and zinc deficiency on immunity. Clin Bull, 1979. 9(1): p. 3−12.
- Goodwin J.S., Prostaglandins and host defense in cancer. Med Clin North Am, 1981.65(4): p. 829−44.
- Gorski A., Castronovo V., Stepien-Sopniewska B., et al., Depressed immune surveillance against cancer: role of deficient T cell: extracellular matrix interactions. Cell Adhes Commun, 1994. 2(3): p. 225−33.
- Gramenzi A., Cursaro C., Andreone P., et al., Thymalfasin: clinical pharmacology and antiviral applications. BioDrugs, 1998. 9(6): p. 477−86.
- Ha U.S., Cho Y.H., Immunostimulation with Escherichia coli extract: prevention of recurrent urinary tract infections. Int J Antimicrob Agents, 2008. 31 Suppl 1: p. S63−7.
- Hadden J.W., The immunology and immunotherapy of breast cancer: an update. Int J Immunopharmacol, 1999. 21(2): p. 79−101.
- Hadden J.W., The treatment of zinc deficiency is an immunotherapy. Int J Immunopharmacol, 1995. 17(9): p. 697−701.
- Haeusler K.G., Schmidt W.U., Fohring F., et al., Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis, 2008. 25(1−2): p. 50−8.
- Hammett T.M., Wu Z., Due T.T., et al., 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam. Addiction, 2008. 103(1): p. 137−45.
- Hardy C.L., Balducci L., Hemopoietic alterations of cancer. Am J Med Sei, 1985. 290(5): p. 196−205.
- Hariri S., McKenna M.T., Epidemiology of human immunodeficiency virus in the United States. Clin Microbiol Rev, 2007. 20(3): p. 478−88, table of contents.
- Hellstrom K.E., Hellstrom I., Snyder H.W., Jr., et al., Blocking (suppressor) factors, immune complexes, and extracorporeal immunoadsorption in tumor immunity. Contemp Top Immunobiol, 1985. 15: p. 213−38.
- Hirakata Y., Furuya N., Tateda K., et al., A protective role for lymphocytes in cyclophosphamide-induced endogenous bacteraemia in mice. J Med Microbiol, 1995. 43(2): p. 141−7.
- Homma S., Toda G., Gong J., et al., Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol, 2001. 36(11): p. 76 471.
- Hua D., Liu M.Y., Cheng Z.D., et al., Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol, 2009. 46(15): p. 287 684.
- Jacobson E.L., Pilaro F., Smith K.A., Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA, 1996. 93(19): p. 10 405−10.
- Jacobson R.H., Immunodeficiency models in characterization of immune responses to parasites—an overview. Vet Parasitol, 1982. 10(2−3): p. 141−54.
- Jeng B.H., Holland G.N., Lowder C.Y., et al., Anterior segment and external ocular disorders associated with human immunodeficiency virus disease. Surv Ophthalmol, 2007. 52(4): p. 329−68.
- Johnson J.T., Rabin B.S., Wagner R.L., Prostaglandin E2 of the upper aerodigestive tract. Ann Otol Rhinol Laryngol, 1987. 96(2 Pt 1): p. 213−6.
- Keller R.H., Calvanico N.J., Suppressor macromolecules. Crit Rev Immunol, 1984. 5(2): p. 149−99.
- Kemeny N., Saltz L., Cohen A., Adjuvant therapy of colorectal cancer. Surg Oncol Clin N Am, 1997. 6(4): p. 699−722.
- Khoury H., Adkins D., Brown R., et al., Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant, 2000. 25(11): p. 1197−201.
- Killeen S.D., Wang J.H., Andrews E.J., et al., Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer, 2006. 95(3): p. 247−52.
- Kim J.Y., Byeon S.E., Lee Y.G., et al., Immunostimulatory Activities of Polysaccharides from Liquid Culture of Pine-Mushroom Tricholoma matsutake. J Microbiol Biotechnol, 2008. 18(1): p. 95−103.
- Klibanov O.M., Clark-Vetri R., Oncologic complications of human immunodeficiency virus infection: changing epidemiology, treatments, and special considerations in the era of highly active antiretroviral therapy. Pharmacotherapy, 2007. 27(1): p. 122−36.
- Kornek M., Lukacs-Kornek V., Limmer A., et al., DOTAP formulated (immune-stimulatory) VEGF-A siRNA increased antitumoral efficacy in orthotopic HCC in murine liver fibrosis. Mol Med, 2008.
- Kramer J.R., Giordano T.P., E1-Serag H.B., Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol, 2007. 5(11): p. 1321−1328 e7.
- Kripke M.L., Effects of UV radiation on tumor immunity. J Natl Cancer Inst, 1990. 82(17): p. 1392−6.
- Landay A., Benning L., Bremer J., et al., Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis, 2003. 188(2): p. 209−18.
- Lane C., Limited immune recovery after freatment with antiretrovirals, IL-2- interview with Clifford Lane, M.D. Interview by John S. James. AIDS Treat News, 1997(No 272): p. 1−5.
- Lau B., Sharrett A.R., Kingsley L.A., et al., C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med, 2006. 166(1): p. 64−70.
- Leon J.A., Goldstein N.I., Fisher P.B., New approaches for the development and application of monoclonal antibodies for the diagnosis and therapy of human cancer. Pharmacol Ther, 1994. 61(1−2): p. 237−78.
- Liner K.J., 2nd, Hall C.D., Robertson K.R., Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. JNeurovirol, 2007. 13(4): p. 291−304.
- Liu J.Y., Wu Y., Zhang X.S., et al., Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother, 2007. 56(10): p. 1597−604.
- M. Schirmer W.H., F. Geisen, J. Thaler and G. Konwalinka, T-cells and natural killer cells after treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Acta Haematol., 1997. 97 p. 180.
- Mackall C.L., T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells, 2000. 18(1): p. 10−8.
- Mackall C.L., T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Oncologist, 1999. 4(5): p. 370−8.
- Mackall C.L., Fleisher T.A., Brown M.R., et al., Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood, 1997. 89(10): p. 3700−7.
- Mackall C.L., Fry T.J., Bare C., et al., IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood, 2001. 97(5): p. 1491−7.
- Mackova N., Suliova J., Repair processes of hemopoiesis after applyingcyclophosphamide. I. Morphological changes in the bone marrow, spleen131and thymus. Folia Haematol Int Mag Klin Morphol Blutforsch, 1986. 113(5): p. 596−604.
- MacLean G.D., Longenecker B.M., New possibilities for cancer therapy with advances in cancer immunology. Can J Oncol, 1994. 4(2): p. 249−54.
- Magdelenat H., Tumour markers in oncology: past, present and future. J Immunol Methods, 1992. 150(1−2): p. 133−43.
- Makar V., Logani M., Szabo I., et al., Effect of millimeter waves on cyclophosphamide induced suppression of T cell functions. Bioelectromagnetics, 2003. 24(5): p. 356−65.
- Matijevic T., Marjanovic M., Pavelic J., Functionally active toll-like receptor 3 on human primary and metastatic cancer cells. Scand J Immunol, 2009. 70(1): p. 18−24.
- McCormick F., Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer, 2001. 1(2): p. 130−41.
- Melief C.J., Kast W.M., T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev, 1995. 145: p. 167−77.
- Merluzzi V.J., Walker M.M., Williams N., et al., Immunoenhancing activity of NPT 15 392: a potential immune response modifier. Int J Immunopharmacol, 1982. 4(3): p. 219−24.
- Milicevic N.M., Milicevic Z., Piletic O., et al., Restriction of regenerative capacity of the rat thymus after the application of cyclophosphamide. J Comp Pathol, 1984. 94(3): p. 425−31.
- Miyazono K., Heldin C.H., Structure, function and possible clinical application of transforming growth factor-beta. J Dermatol, 1992. 19(11): p. 644−7.
- Mocellin S., Wang E., Marineola F.M., Cytokines and immune response in the tumor microenvironment. J Immunother, 2001. 24(5): p. 392−407.
- Mohan H., Bal A., Garg S., et al., Cytomegalovirus-associatedpseudotumor simulating gastric malignancy in acquired immunodeficiency syndrome: a case report with review of literature. Jpn J Infect Dis, 2007. 60(2−3): p. 1346.
- Morris H.J., Bermudez R.C., Carrillo O., et al., Are the peptide sequences encrypted in food Chlorella protein a possible explanation for the immunostimulatory effects of microalgal supplements? Med Hypotheses, 2008. 70(4): p. 896.
- Motoyoshi Y., Kaminoda K., Saitoh O., et al., Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep, 2006. 16(1): p. 141−6.
- Murphy G.P., Brede H.D., Weber H.W., et al., Renal allotransplantation in the baboon with chemical immunosuppression. S Air Med J, 1968: p. Suppl:26−37.
- N. Kamani A.K., A. Carroll, D. Campbell, N. Bunin, Immune reconstitution after autologous purged bone marrow transplantation in children. J. Pediatr. Hematol. Oncol., 2000. 22: p. 13.
- Nagorsen D., Thiel E., Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res, 2006. 12(10): p. 3064−9.
- Niedzielska I., Niedzielski Z., Tkacz M., et al., Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer. J Physiol Pharmacol, 2009. 60 SuppI 1: p. 65−71.
- Niklinski J., Furman M., Clinical tumour markers in lung cancer. Eur J Cancer Prev, 1995. 4(2): p. 129−38.
- Nishikawa H., Tanida K., Ikeda H., et al., Role of SEREX-defined immunogenic wild-type cellular molecides in the development of tumor-specific immunity. Proc Natl Acad Sci U S A, 2001. 98(25): p. 14 571−6.
- Nouri-Shirazi M., Banchereau J., Fay J., et al., Dendritic cell based tumor vaccines. Immunol Lett, 2000. 74(1): p. 5−10.
- Ohnishi K., Yamanishi H., Naito K., et al., Reconstitution of peripheral blood lymphocyte subsets in the long-term disease-free survivors of patients with acute myeloblastic leukemia. Leukemia, 1998. 12(1): p. 52−8.
- Okamoto M., Kasetani H., Kaji R., et al., cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother, 1998. 47(4): p. 233−41.
- P.K. Ray. In: F.A. Salinas and M.G. Hanna J., Editors, complexes and human cancer, Plenum, New York (1985), pp. 147—211. .
- Palucka K., Ueno H., Fay J., et al., Dendritic cells and immunity against cancer. J Intern Med. 269(1): p. 64−73.
- Palucka K., Ueno H., Roberts L., et al., Dendritic cells: are they clinically relevant? Cancer J. 16(4): p. 318−24.
- Paone A., Starace D., Galli R., et al., Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis, 2008. 29(7): p. 1334−42.
- Parmiani G., Castelli C., Dalerba P., et al, Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst, 2002. 94(11): p. 805−18.
- Peate I., Human immunodeficiency virus and the older person. Br J Nurs, 2007. 16(10): p. 606−10.
- Penn I., Depressed immunity and the development of cancer. Cancer Detec. Prev. 18 (1994), pp. 241−252.
- Ponce R., Adverse consequences of immunostimulation. J Immunotoxicol, 2008. 5(1): p. 33−41.
- Popovic D., Gill L., Sisson G., et al., Detection and localization of tumor-associated immune components of head and neck squamous cell carcinomas. Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol, 1976. 82(2): p. 119−30.
- Prakash, Gupta V., Singh S.M., et al., Effect of intrauterine exposure of murine fetus to cyclophosphamide on development of thymus. Immunopharmacol Immunotoxicol, 2007. 29(1): p. 17−30.
- Qin C.G., Huang K.X., Xu H.B., Effect of Misgurnus anguillicaudatus polysaccharide on immune responses of splenocytes in mice. Acta Pharmacol Sin, 2002. 23(6): p. 534−8.
- Ralph P., Warren M.K., Lee M.T., et al., Inducible production of human macrophage growth factor, CSF-1. Blood, 1986. 68(3): p. 633−9.
- Resser J.R., Carbone D.P., Immunotherapy of head and neck cancer. Curr Opin Oncol, 1998. 10(3): p. 226−32.
- Rocchi R., Kimura H., Tzou S.C., et al., Toll-like receptor-MyD88 and Fc receptor pathways of mast cells mediate the thyroid dysfunctions observed during nonthyroidal illness. Proc Natl Acad Sei USA, 2007. 104(14): p. 6019−24.
- Rosenberg S.A., Yang J.C., Topalian S.L., et al., Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA, 1994. 271(12): p. 907−13.
- Sabiston B.H., Rose J.E., Cinader B., Temperature stress and immunity in mice: effects of environmental temperature on the antibody response to human immunoglobulin of mice, differing in age and strain. J Immunogenet, 1978. 5(3): p. 197−212.
- Sahin U., Tureci 0., Pfreundschuh M., Serological identification of human tumor antigens. Curr Opin Immunol, 1997. 9(5): p. 709−16.
- Salgaller M.L., Tjoa B.A., Lodge P.A., et al., Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol, 1998. 18(1−2): p. 109−19.
- Samet J.H., Walley A.Y., Bridden C., Illicit drugs, alcohol, and addiction in human immunodeficiency virus. Panminerva Med, 2007. 49(2): p. 67−77.
- Sarin A., Wu M.L., Henkart P.A., Different interleukin-1 beta converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli. J Exp Med, 1996. 184(6): p. 244 550.
- Schatten S., Granstein R.D., Drebin J.A., et al., Suppressor T cells and the immune response to tumors. Crit Rev Immunol, 1984. 4(4): p. 335−79.
- Schloen L.H., Fernandes G., Garofalo J.A., et al., Nutrition, immunity and cancer—a review. Part II: zinc, immune function and cancer. Clin Bull, 1979. 9(2): p. 63−75.
- Sefc L., Psenak O., Sykora V., et al., Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen. J Hematother Stem Cell Res, 2003. 12(1): p. 47−61.
- Selvaraj P., Yerra A., Tien L., et al., Custom designing therapeutic cancer vaccines: Delivery of immunostimulatory molecule adjuvants by protein transfer. Hum Vaccin, 2008. 4(5).
- Shackelford J., Pagano J.S., Role of the ubiquitin system and tumor viruses in AIDS-related cancer. BMC Biochem, 2007. 8 SuppI 1: p. S8.
- Shakoor Z., Serial evaluation of percentage of activated T-lymphocytes in peripheral blood of human immunodeficiency virus infected individuals as a prognostic marker. Saudi Med J, 2003. 24(6): p. 632−6.
- Shim J.Y., Han Y., Ahn J.Y., et al., Chemoprotective and adjuvant effects of immunomodulator ginsan in cyclophosphamide-ti'eated normal and tumor bearing mice. Int J Immunopathol Pharmacol, 2007. 20(3): p. 487−97.
- Slater L.M., Stupecky M., Sweet P., et al., Enhancement of leukemia rejection by mice successfully treated for LI210 leukemia due to low dose compared to high dose VP-16. Leuk Res, 2002. 26(2): p. 203−6.
- Smith K.O., Gehle W.D., Newman J.T., et al., An approach to the serodiagnosis of human lung cancer. Cell culture lines reactive as antigens with tumor patients' sera. Cancer, 1976. 38(1): p. 157−65.
- So E.Y., Ouchi T., The application of Toll like receptors for cancer therapy. Int J Biol Sci. 6(7): p. 675−81.
- Sorvari T.E., Toivanen A., Transplantation of bursal stem cells into cyclophosphamide-treated chicks. Lymphoid repopulation of splenic structures. Scand J Immunol, 1976. 5(4): p. 317−21.
- Soti C., Csermely P., Molecular chaperones in the etiology and therapy of cancer. Pathol Oncol Res, 1998. 4(4): p. 316−21.
- Sporn M.B., Roberts A.B., Transforming growth factor-beta. Multiple actions and potential clinical applications. JAMA, 1989. 262(7): p. 938−41.
- Srivastava P.K., Amato R.J., Heat shock proteins: the 'Swiss Army Knife' vaccines against cancers and infectious agents. Vaccine, 2001. 19(17−19): p. 2590−7.
- Steele T.A., Chemotherapy-induced immunosuppression and reconstitution of immune function. Leuk Res, 2002. 26(4): p. 411−4.
- Sulitzeanu D., Immunosuppressive factors in human cancer. Adv Cancer Res, 1993. 60: p. 247−67.
- Svedsersky L.P., Minton J.P., Kolodziej B.J., Nonspecific immunosuppression by cultured lymphocyte supernates of cancer patients. J Surg Oncol, 1980. 14(3): p. 235−43.
- Syed M.I., Clark L.J., Sturrock R.D., Unintended benefits of immunosupression on autoimmune disease due to chemoradiation therapy for head and neck cancer. Am J Otolaryngol, 2008. 29(1): p. 63−5.
- Tharakan S.T., Kuttan G., Kuttan R., et al., Effect of AC II, an herbal formulation in cyclophosphamide-induced immunosuppression in BALB/c mice—Implication in HIV treatment. Immunol Invest, 2007. 36(2): p. 147−57.
- Thoman M.L., Weigle W.O., The cellular and subcellular bases of immunosenescence. Adv Immunol, 1989. 46: p. 221−61.
- Thomas L., Asad M., Hrishikeshavan H.J., et al., Effect of centchroman on cellular and humoral immunity. Indian J Physiol Pharmacol, 2007. 51(4): p. 387−94.
- Tisdale M.J., Role of prostaglandins in metastatic dissemination of cancer. Minireview on cancer research. Exp Cell Biol, 1983. 51(5): p. 250−6.
- Tjoa B.A., Erickson S.J., Bowes V.A., et al., Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate, 1997. 32(4): p. 272−8.
- Toes R.E., Offringa R., Feltkamp M.C., et al., Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring Inst Mitt, 1994(94): p. 7286.
- Topalian S.L., MHC class II restricted tumor antigens and the role of CD4+ Tcells in cancer immunotherapy. Curr Opin Immunol, 1994. 6(5): p. 741−5.
- Tsang J.Y., Tanriver Y., Jiang S., et al., Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression. Transpl Immunol, 2009. 21(4): p. 203−9.
- Tsuji S., Matsumoto M., Takeuchi O., et al., Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun, 2000. 68(12): p. 6883−90.
- Tuyaerts S., Dendritic cell therapy for oncology roundtable conference. J Immune Based Ther Vaccines. 9(1): p. 1.
- Tweardy D.J., Caracciolo D., Valtieri M., et al., Tumor-derived growth factors that support proliferation and differentiation of normal and leukemic hemopoietic cells. AnnN Y Acad Sci, 1987. 511: p. 30−8.
- Uronis H.E., Bendell J.C., Anal cancer: an overview. Oncologist, 2007. 12(5): p. 524−34.
- Uslu A., Nart A., Tasli F.A., et al., Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation. Nephrology (Carlton), 2008. 13(1): p. 80−6.
- Veltri R.W., Rodman S.M., Maxim P.E., et al., Immune complexes, serum proteins, cell-mediated immunity, and immune regulation in patients withsquamous cell carcinoma of the head and neck. Cancer, 1986. 57(12): p. 2295−308.
- Verastegui E., Morales R., Barrera J.L., et al., Immunological approach in the evaluation of regional lymph nodes of patients with squamous cell carcinoma of the head and neck. Clin Immunol, 2002. 102(1): p. 37−47.
- Vermund S.H., Yamamoto N., Co-infection with human immunodeficiency virus and tuberculosis in Asia. Tuberculosis (Edinb), 2007. 87 SuppI 1: p. SI 8−25.
- Yijay-Kumar M., Aitken J.D., Sanders C.J., et al., Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol, 2008. 180(12): p. 8280−5.
- Virag L., Kerekgyarto C., Fachet J., A simple, rapid and sensitive fluorimetric assay for the measurement of cell-mediated cytotoxicity. J Immunol Methods, 1995. 185(2): p. 199−208.
- Vlock D.R., Immune complexes and malignancy. Immunol Ser, 1990. 53: p. 555−86.
- Vujanovic N.L., Yasumura S., Hirabayashi H., et al., Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol, 1995. 154(1): p. 281−9.
- Whiteside T.L., Immunobiology and immunotherapy of head and neck cancer. Curr Oncol Rep, 2001. 3(1): p. 46−55.
- Whiteside T.L., Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother, 1999. 48(7): p. 346−52.
- Whiteside T.L., Vujanovic N.L., Herberman R.B., Natural killer cells and tumor therapy. Curr Top Microbiol Immunol, 1998. 230: p. 221−44.
- Williams K., Schwartz A., Corey S., et al., Proliferating cellular nuclear antigen expression as a marker of perivascular macrophages in simian immunodeficiency virus encephalitis. Am J Pathol, 2002. 161(2): p. 575−85.
- Yin M.T., Dobkin J.F., Grbic J.T., Epidemiology, pathogenesis, and management of human immunodeficiency virus infection in patients with periodontal disease. Periodontol 2000, 2007. 44: p. 55−81.
- Yoon T.J., Kim J.Y., Kim H., et al., Anti-tumor immunostimulatory effect of heat-killed tumor cells. Exp Mol Med, 2008. 40(1): p. 130−44.
- Young M.R., Lathers D.M., Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol, 1999. 21(4): p. 241−52.
- Yu L., Chen S., Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother, 2008. 57(9): p. 1271−8.
- Yu N., Zhang S., Zuo F., et al., Cultured human melanocytes express functional toll-like receptors 2−4, 7 and 9. J Dermatol Sei, 2009. 56(2): p.113.20.
- Yudin M.H., Prosen T.L., Landers D.V., Multiple-marker screening in human immunodeficiency virus-positive pregnant women: Screen positivity rates with the triple and quad screens. Am J Obstet Gynecol, 2003. 189(4): p. 973−6.
- Zola H., Medical applications of leukocyte surface molecules—the CD molecules. Mol Med, 2006. 12(11−12): p. 312−6.
- Zwiorek K., Bourquin C., Battiany J., et al., Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm Res, 2008. 25(3): p. 551−62.